Select Equity Group L.P. Decreases Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Select Equity Group L.P. lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 79.7% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 137,839 shares of the life sciences company's stock after selling 542,287 shares during the period. Select Equity Group L.P. owned approximately 0.09% of Illumina worth $18,419,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Golden State Wealth Management LLC bought a new position in shares of Illumina in the fourth quarter valued at about $32,000. Assetmark Inc. lifted its holdings in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after purchasing an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Illumina in the 4th quarter worth about $45,000. Lee Danner & Bass Inc. acquired a new position in Illumina in the fourth quarter valued at about $48,000. Finally, V Square Quantitative Management LLC grew its position in Illumina by 50.6% in the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock valued at $52,000 after acquiring an additional 132 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Price Performance

Shares of ILMN traded up $1.26 during mid-day trading on Tuesday, reaching $84.21. The stock had a trading volume of 1,984,525 shares, compared to its average volume of 2,316,784. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The business has a fifty day moving average of $78.46 and a 200 day moving average of $110.42. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The firm has a market cap of $13.33 billion, a price-to-earnings ratio of -10.96, a PEG ratio of 1.60 and a beta of 1.35.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.01. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Illumina's quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.98 EPS. Equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Insider Transactions at Illumina

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of the business's stock in a transaction on Monday, May 12th. The shares were acquired at an average price of $81.21 per share, with a total value of $495,381.00. Following the transaction, the chief financial officer now owns 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.60% of the company's stock.

Wall Street Analyst Weigh In

ILMN has been the topic of several research reports. Stephens restated an "overweight" rating and set a $105.00 price target on shares of Illumina in a report on Tuesday. JPMorgan Chase & Co. decreased their price objective on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Royal Bank of Canada lowered their target price on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 8th. Canaccord Genuity Group decreased their target price on shares of Illumina from $92.00 to $87.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Finally, HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $128.15.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.